Polydatin is therapeutic in cardiovascular disease by increasing superoxide dismutase (SOD) activity, inhibiting cardiomyocyte hypertrophy and regulating cellular calcium levels (Ding et al., 2014; Zhang et al., 2015; Yu et al., 2018). This evidence concerns the gene SOD1 and cardiovascular disorder.